KATY, TX – July 31, 2026 – PRESSADVANTAGE –

HealthSeers, Inc. today announced the launch of its new website and blog, giving healthcare providers, medical professionals, and industry stakeholders a central resource to follow the company’s progress as it works toward FDA clearance and commercialization of Cairdio, its AI-powered cardiac risk assessment device. The site will also serve as a home for the company’s ongoing thought leadership on pediatric cardiac screening, publishing regular insights grounded in current research and clinical data.

The launch comes amid growing recognition of the limitations in current pediatric cardiac screening methods. New data shows that 1 in 300 youth in the United States has a potentially life-threatening heart condition, and 80 percent of young people who experience sudden cardiac arrest show no symptoms beforehand. The company’s first blog post, “Your Child’s Physical Might Be Missing This,” examines these gaps in detail, noting that sudden cardiac arrest is the leading cause of death on school campuses and among student athletes in the U.S., with between 7,000 and 23,000 cases occurring annually in young people and a survival rate of only 10 percent.

“We wanted a home base where physicians, researchers, and the broader medical community can follow our work as we move Cairdio through the FDA process,” said Rick Jones, CEO of HealthSeers, Inc. “At the same time, this gives us a platform to publish substantive thinking on where pediatric cardiac screening falls short today, and where we believe the field is headed.”

Cairdio is an AI-powered cardiac risk assessment device currently progressing through FDA clearance. The technology uses a four-track synchronized recording system that captures heart sounds from multiple auscultation points simultaneously, analyzing patterns that traditional single-point stethoscopes routinely miss. Research indicates that approximately half of clinically meaningful cardiac findings go undetected during routine stethoscope examinations, due to the subtle nature of many heart abnormalities and the limitations of traditional auscultation methods — one of the core problems Cairdio is designed to address.

The new site and blog will track key milestones in Cairdio’s regulatory and development journey, while also publishing regular content on cardiac screening research, pediatric heart health statistics, and developments in detection technology. The company expects the resource to be of particular interest to healthcare providers, school nurses, sports coaches, and medical professionals seeking better tools for early cardiac condition detection, as well as to partners and investors following the company’s path to market.

“The gap in pediatric cardiac screening affects every community, with roughly three to four children in every average-sized elementary school having an undetected heart condition,” Jones added. “As we work toward clearance, we also want to contribute meaningfully to the conversation around what better screening can look like — and give people a reliable place to follow both.”

The platform also includes practical resources for parents, including questions to ask pediatricians about cardiac screening protocols, warning signs to monitor, and guidance on assessing family cardiac history.

HealthSeers, Inc. specializes in developing artificial intelligence-powered medical assessment tools. The company’s Cairdio product integrates PhonoCardioGraphy technology with AI analysis to enhance cardiac screening capabilities. Founded with a mission to transform cardiac assessment globally, HealthSeers works with leading cardiologists and medical institutions to advance early detection of heart conditions in pediatric populations.

###

For more information about HealthSeers, Inc., contact the company here:

Cairdio – by HealthSeers
Rick Jones
info@healthseers.com
Katy, Texas

Media gallery

About The Author
PressAdvantage